**Overview of Retinal Vein Occlusion (RVO)**

|  |  |
| --- | --- |
| Resource | Address |
| Anderson FA, Spencer FA. Risk factors for venous thromboembolism. *Circulation.* 2003;107(23 suppl 1):I9-I16. | <https://www.ahajournals.org/doi/10.1161/01.CIR.0000078469.07362.E6> |
| Christoffersen NLB, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. *Ophthalmology.* 1999;106:2054-2062. | <https://www.aaojournal.org/article/S0161-6420(99)90483-9/fulltext> |
| Fegan CD. Central retinal vein occlusion and thrombophilia. *Eye (Lond).* 2002;16:98-106. | <https://www.nature.com/articles/6700040> |
| Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal Vein Occlusions Preferred Practice Pattern®. *Ophthalmology.* 2020;127:P288-P320. | <https://www.aaojournal.org/article/S0161-6420(19)32096-2/fulltext> |
| Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. *J Ophthalmol.* 2014;724780. | <https://www.hindawi.com/journals/joph/2014/724780/> |
| Pinhas A, Dubow M, Shah N, et al. Fellow eye changes in patients with nonischemic central retinal vein occlusion: Assessment of perfused foveal microvascular density and identification of nonperfused capillaries. *Retina*. 2015;35:2028-2036. | <https://journals.lww.com/retinajournal/Abstract/2015/10000/FELLOW_EYE_CHANGES_IN_PATIENTS_WITH_NONISCHEMIC.14.aspx> |
| Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus.* 2011;9:120-138. | <https://www.bloodtransfusion.it/articolo.aspx?idart=002216> |
| Schaab T, Padidam S, Gill MK. Navigating retinal imaging. *Ophthalmol Manage.* 2018;22:18-20, 22-24. | <https://www.ophthalmologymanagement.com/issues/2018/july-2018/navigating-retinal-imaging> |
| Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: A systematic review and meta-analysis of prevalence, incidence, and risk factors. *J Glob Health*. 2019;9:010427. | <https://jogh.org/documents/issue201901/jogh-09-010427.pdf> |

**The Role of Vascular Endothelial Growth Factor (VEGF) in RVO**

|  |  |
| --- | --- |
| Resource | Address |
| Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J M*ed. 1994;331:1480-1487. | <https://www.nejm.org/doi/full/10.1056/NEJM199412013312203> |
| Christoffersen NLB, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. *Ophthalmology.* 1999;106:2054-2062. | <https://www.aaojournal.org/article/S0161-6420(99)90483-9/fulltext> |
| Fegan CD. Central retinal vein occlusion and thrombophilia. *Eye (Lond).* 2002;16:98-106. | <https://www.nature.com/articles/6700040> |
| Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol.* 2006;244:309-315. | <https://link.springer.com/article/10.1007/s00417-004-1087-4> |

**Management of RVO-Associated Macular Edema**

|  |  |
| --- | --- |
| Resource | Address |
| Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. *Ophthalmology*. 2010;117:1124-1133.e1. | <https://www.aaojournal.org/article/S0161-6420(10)00186-7/fulltext> |
| Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. *Ophthalmology*. 2011;118:1594-1602. | <https://www.aaojournal.org/article/S0161-6420(11)00181-3/fulltext> |
| Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. *Am J Ophthalmol*. 2013;155:429-437.e7. | <https://www.ajo.com/article/S0002-9394(12)00682-4/fulltext> |
| Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. *Ophthalmology.* 2010;117:1102-1112.e1. | <https://www.aaojournal.org/article/S0161-6420(10)00185-5/fulltext> |
| Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. *Ophthalmology*. 2011;118:2041-2049. | <https://www.aaojournal.org/article/S0161-6420(11)00224-7/fulltext> |
| Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. *Ophthalmology*. 2016:123:330-336. | <https://www.aaojournal.org/article/S0161-6420(15)01113-6/fulltext> |
| Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal Vein Occlusions Preferred Practice Pattern®. *Ophthalmology.* 2020;127:P288-P320. | <https://www.aaojournal.org/article/S0161-6420(19)32096-2/fulltext> |
| Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. *Retina*. 2009;29:46-51. | <https://journals.lww.com/retinajournal/Abstract/2009/01000/EVALUATION_OF_THE_SAFETY_AND_PERFORMANCE_OF_AN.8.aspx> |
| Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology*. 2010;117:1134-1146.e3. | <https://www.aaojournal.org/article/S0161-6420(10)00311-8/fulltext> |
| Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. *Ophthalmology.* 2012;119:802-809. | <https://www.aaojournal.org/article/S0161-6420(11)01151-1/fulltext> |
| Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. *J Ophthalmol.* 2014;724780. | <https://www.hindawi.com/journals/joph/2014/724780/> |
| Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the phase 3 GALILEO study. *Ophthalmology.* 2014;121:202-208. | <https://www.aaojournal.org/article/S0161-6420(13)00730-6/fulltext> |
| Regillo C. ARVO: Retina focuses on anti-VEGF drugs. *Rev Ophthalmol.* May 2, 2011. | <https://www.reviewofophthalmology.com/article/arvo-retina-focuses-on-anti-vegf-drugs> |
| Scott IU, VanVeldhuisen PC, Ip MS, et al. SCORE2 report 2: Study design and baseline characteristics. *Ophthalmology.* 2017;124:245-256. | <https://www.aaojournal.org/article/S0161-6420(16)30902-2/fulltext> |
| Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: The SCORE2 randomized clinical trial. *JAMA.* 2017;2072-2087. | <https://jamanetwork.com/journals/jama/fullarticle/2626260> |
| Steinle N, et al. The business of medical retina: overcoming payor challenges. *Retina Today.* October 1, 2020;(suppl). | <https://assets.bmctoday.net/retinatoday/pdfs/1020RT_Evolve%202013_Market%20Access%202020_STAND%20ALONE%20SUPP.pdf> |